Chris joined the board of HTE in 2015 and brings twenty-five years of demonstrated success driving medical device and diagnostic products from concept through launch and all stages of market adoption in both venture funded and Fortune 500 companies.
Currently Chairman of Mologic Ltd, NED for Deltex Medical, and Special Advisor to MediSeive and StableLab, Chris is a US national who came to the UK in 2008 to become CEO of GlySure. From 2008-2015 he led the development of the world’s first continuous intravascular glucose sensor from laboratory proof of concept to CE approval. Prior to joining GlySure he was CEO of Tensys Medical developing and commercialising the first clinically acceptable, continuous, non-invasive blood pressure monitor resulting in the sale of the company in 2008.
Chris also spent nine years with Nellcor Inc, a division of Tyco Healthcare, most recently as VP of Marketing responsible for the $700M WW pulse oximetry and critical care businesses. Prior to this, he spent six years in sales and marketing management positions at BioGenex Laboratories.
Chris is a graduate of Yale University with a Bachelor of Science Degree in Molecular Biophysics and Biochemistry.